L M Shulman
Affiliation: University of Maryland
- Non-recognition of depression and other non-motor symptoms in Parkinson's diseaseL M Shulman
Department of Neurology, University of Maryland School of Medicine, 22 S Greene Street, Baltimore, MD 21201, USA
Parkinsonism Relat Disord 8:193-7. 2002..Depression, anxiety, fatigue and sleep disorders occur commonly in patients with Parkinson's disease (PD). These non-motor symptoms often contribute to the reduction of functional abilities in PD patients...
- Comorbidity of the nonmotor symptoms of Parkinson's diseaseL M Shulman
Department of Neurology, University of Maryland School of Medicine, 22 S. Greene St, Baltimore, MD 21201, USA
Mov Disord 16:507-10. 2001..These results suggest that recognition of these diverse nonmotor symptoms may be enhanced by looking for others when one nonmotor symptom has been identified...
- Psychogenic seizures and psychogenic movement disorders: are they the same patients?J L Hopp
Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA
Epilepsy Behav 25:666-9. 2012..These similar profiles suggest that PNES and PMD may not be distinct or separate entities and that collaborative investigative efforts and management are warranted...
- Cocaine-induced persistent dyskinesiasW J Weiner
Department of Neurology, University of Maryland School of Medicine, Baltimore 21201, USA
Neurology 56:964-5. 2001..The abnormal movements and behavior disorder persisted after a 20-month cocaine-free period...
- When do patients with Parkinson disease disclose their diagnosis?S Haines
Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Neurology 67:488-90. 2006..Patients who delayed disclosure were more likely male, younger, and employed. There is considerable variability among patients with PD in the time to disclose their diagnosis...
- Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trialH H Fernandez
Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
Parkinsonism Relat Disord 16:16-20. 2010..6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD)...
- Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyJ M Miyasaki
University of Toronto, Canada
Neurology 66:996-1002. 2006..1) What tools are effective to screen for depression, psychosis, and dementia in PD? 2) What are effective treatments for depression and psychosis in PD? 3) What are effective treatments for PD dementia or dementia with Lewy bodies (DLB)?..